Short Interest To Observe: It Seems Albany Molecular Research (NASDAQ:AMRI) Will Go Up. Just Reported Less Shorted Shares

November 23, 2016 - By Nellie Frank   ·   0 Comments

Short Interest To Observe: It Seems Albany Molecular Research (NASDAQ:AMRI) Will Go Up. Just Reported Less Shorted Shares

The stock of Albany Molecular Research (NASDAQ:AMRI) registered a decrease of 3.78% in short interest. AMRI’s total short interest was 5.21 million shares in November as published by FINRA. Its down 3.78% from 5.41 million shares, reported previously. With 130,500 shares average volume, it will take short sellers 40 days to cover their AMRI’s short positions. The short interest to Albany Molecular Research’s float is 34.09%. About 85,282 shares traded hands. Albany Molecular Research, Inc. (NASDAQ:AMRI) has risen 6.79% since April 21, 2016 and is uptrending. It has outperformed by 1.46% the S&P500.

Albany Molecular Research, Inc. is a global contract research and manufacturing company. The company has a market cap of $743.82 million. The Firm provides drug discovery, development, and manufacturing services. It currently has negative earnings. The Firm operates through three divisions: Discovery and Development Services , Active Pharmaceutical Ingredients (API) and Drug Product Manufacturing (DPM).

Insitutional Activity: The institutional sentiment decreased to 0.95 in Q2 2016. Its down 0.49, from 1.44 in 2016Q1. The ratio is negative, as 12 funds sold all Albany Molecular Research, Inc. shares owned while 31 reduced positions. 12 funds bought stakes while 50 increased positions. They now own 27.11 million shares or 11.37% less from 30.58 million shares in 2016Q1.
New York State Teachers Retirement Sys holds 22,193 shares or 0% of its portfolio. Kennedy Cap Mgmt reported 46,248 shares or 0.01% of all its holdings. Us Natl Bank De has 4,650 shares for 0% of their US portfolio. Fisher Asset Ltd Llc holds 0.01% or 203,450 shares in its portfolio. Netols Asset Mgmt Inc last reported 371,423 shares in the company. Vaughan Nelson Inv Mngmt L P accumulated 1.78M shares or 0.3% of the stock. Woodmont Inv Counsel Limited Liability Corporation last reported 4,773 shares in the company. Shinko Asset Mngmt Company Ltd has 203,450 shares for 0.02% of their US portfolio. California State Teachers Retirement Systems holds 0% or 54,496 shares in its portfolio. Strs Ohio owns 47,400 shares or 0% of their US portfolio. Bancorporation Of America De holds 3,314 shares or 0% of its portfolio. Moreover, Blackrock has 0% invested in Albany Molecular Research, Inc. (NASDAQ:AMRI) for 4,060 shares. First Quadrant Ltd Partnership Ca owns 39,700 shares or 0.01% of their US portfolio. Panagora Asset Mngmt has 0% invested in the company for 6,121 shares. Thrivent Fincl For Lutherans accumulated 73,920 shares or 0% of the stock.

Insider Transactions: Since May 31, 2016, the stock had 0 buys, and 4 insider sales for $208,651 net activity. On Tuesday, August 9 Hagen Steven R sold $21,421 worth of the stock or 1,401 shares. $72,050 worth of shares were sold by OCONNOR KEVIN on Tuesday, May 31. $102,000 worth of Albany Molecular Research, Inc. (NASDAQ:AMRI) shares were sold by HENDERSON LORI M..

AMRI Company Profile

Albany Molecular Research, Inc., incorporated on August 6, 1998, is a global contract research and manufacturing company. The Firm provides drug discovery, development, and manufacturing services. The Firm operates through three divisions: Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API) and Drug Product Manufacturing (DPM). The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small-scale commercial manufacturing. API includes pilot to commercial scale manufacturing of active pharmaceutical ingredients and intermediates and high potency and controlled substance manufacturing. DPM includes pre-formulation, formulation and process development through commercial scale production of complex liquid-filled and lyophilized injectable formulations. The Firm supplies a range of services and technologies supporting the discovery and development of pharmaceutical products, the manufacturing of API and drug product for new and generic drugs, as well as research, development and manufacturing for the agrochemical and other industries.

More recent Albany Molecular Research, Inc. (NASDAQ:AMRI) news were published by: Prnewswire.com which released: “AMRI to Present Two Posters at AAPS 2016” on November 14, 2016. Also Moodys.com published the news titled: “Moody’s affirms Albany Molecular’s B3 CFR following announced acquisition of …” on May 09, 2016. Prnewswire.com‘s news article titled: “SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation …” with publication date: August 09, 2016 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Nellie Frank


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>